Linking Proteins to Drugs

Functional RDF Utilization

Brian Kirk
Rice University
07/29/10
Introduction

• Scientific methodology
• Preliminary results
• Implementation
• Challenges
• Conclusions
Working Collaboration

• Emily Doughty and Jonathan Mortensen (who contributed the version of NDF-RT that we are using)

• The subsequent research was produced as a joint exercise between Emily and myself in all aspects including planning, creation of system, and application of the research

• In the interest of creating this presentation, I will be presenting on the building aspects of the project, while later Emily will present on some of the findings
Project Goals

• To find relationships between Drug Properties and Protein Features
  – Some research questions
    • How closely do drugs interact with proteins containing the same domain classes as with other known drug targets?
    • How closely do drugs that treat the same disease relate to proteins that are known to cause said disease?
    • How often do known mutations correspond to domains within the literature?
    • How well does the presence of a drug target within a given molecular pathway correspond to noted methods of action of other drugs that affect the same pathway?
Project Goals

• To find relationships between Drug Properties and Protein Features
  – Some research questions
    • How closely do drugs interact with proteins containing the same domain classes as with other known drug targets?
    • How closely do drugs that treat the same disease relate to proteins that are known to cause said disease?
    • How often do known mutations correspond to domains within the literature?
    • How well does the presence of a drug target within a given molecular pathway correspond to noted methods of action of other drugs that affect the same pathway?
Pharmacogenetics

• Relationship between Genes (Genetics) and Drugs, (Pharmacology)

• Current state of the art reflects research conducted in:
  – Elucidated physiological effects
  – Measuring gene expression changes
  – Genotyping specific drug responses
    • Mutations on Cytochrome P450 2C9 affect ability to metabolize the drug; leads to needing lower dose
Previous Work: Text Mining

- **EMU** - (Developed by Emily and her lab)
  - Takes PubMed abstracts that have been pre-filtered by MeSH terms and identifies mentions of nucleotide or amino acid mutations and then verifies that that mutation is possible with the genes or proteins mentioned in the abstract

- Drug names from the same PubMed abstracts extracted by **MetaMap** and converted into RxNorm concepts
Example: Drug “Warfarin”

drug_class: Anticoagulants and Blood Products/modifiers/volume expanders
may_treat: Thrombophlebitis, Thromboembolism, Atrial Fibrillation...
may_prevent: Venous Thrombosis, Myocardial Infarction, Thromboembolism...
CI_with: Eclampsia, Cerebral Hemorrhage, Ascorbic Acid Deficiency...
has_Ingredient: Warfarin
has_MoA: Vitamin K Epoxide Reductase Inhibitors
has_PE Decreased Coagulation Factor Concentration
site_of_metabolism: Hepatic Metabolism
Protein Features

Pathways—Reactome and BioCyc describe ~1000 genomic and metabolic pathways

Functional properties—Gene Ontology describes the Biological Process, Cellular Component, Molecular Function

Disease—PharmGKB relates genes to drugs to diseases across ~6000 relationships

Domains—Pfam and NCBI Structure describe the structural and functional domains for proteins
Traversing the graph
Preliminary Result

- Looking at the drug cortisone we find that proteins that are related to this drug and their domains

<table>
<thead>
<tr>
<th>Protein</th>
<th>Domain</th>
</tr>
</thead>
<tbody>
<tr>
<td>HSD11B2</td>
<td>Hormone_recep, zf-C4, HOLI, ZnF_C4, Androgen_recep, adh_short, DlTE, FabG COG4221, p450, CypX, cNMP_binding, Crp cNMP, Rila, AP_ED, Aldo_ket_red, ARA1, Tas, COG4989</td>
</tr>
<tr>
<td>CYP21A2</td>
<td></td>
</tr>
<tr>
<td>PRKAR1A</td>
<td></td>
</tr>
<tr>
<td>NR3C2</td>
<td></td>
</tr>
<tr>
<td>NR0B1</td>
<td></td>
</tr>
<tr>
<td>AKR1D1</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drugs</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>CORTISONE</td>
<td></td>
</tr>
<tr>
<td>HYDROCORTISONE</td>
<td></td>
</tr>
<tr>
<td>DEXAMETHASONE</td>
<td></td>
</tr>
<tr>
<td>TRIAMCINOLONE</td>
<td></td>
</tr>
<tr>
<td>PREDNISOLONE</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Proteins</th>
<th>12 proteins</th>
</tr>
</thead>
<tbody>
<tr>
<td>150 drugs</td>
<td></td>
</tr>
</tbody>
</table>
IMPLEMENTATION
Linked Data on the Web
Biological Resources
Resource Description Framework (RDF)

- **Semantic Web (Most commonly seen as RSS)**
  - Subject – Predicate – Object Triples

- **For Example: A table such as:**

<table>
<thead>
<tr>
<th>Entrez Id</th>
<th>Ensembl Id</th>
<th>UniProt Id</th>
<th>Name</th>
<th>Symbol</th>
</tr>
</thead>
<tbody>
<tr>
<td>1017</td>
<td>ENSG00000123374</td>
<td>P24941</td>
<td>cyclin-dependent kinase 2</td>
<td>CDK2</td>
</tr>
<tr>
<td>1019</td>
<td>ENSG00000135446</td>
<td>P11802</td>
<td>cyclin-dependent kinase 4</td>
<td>CDK4</td>
</tr>
<tr>
<td>1021</td>
<td>ENSG00000105810</td>
<td>Q00534</td>
<td>cyclin-dependent kinase 6</td>
<td>CDK6</td>
</tr>
</tbody>
</table>

- `<URI_Entrez#1017> <URI#has_name> (“cyclin-dependent kinase 2” or <URI_uniprot#P24941>)`
  - Subject       Predicate       Object

- **URI: Uniform Resource Identifier**
  - Similar to URL, only identifies resource location
    - Example: http://purl.uniprot.org/uniprot
Triple Store

A Database manager that has been specifically designed to deal with indexing and storing RDF triples, can functionally deal with billions of triples (1.5 B)

Virtuoso allows web access, has good scalability, and is open source
SPARQL Queries

from <http://localhost:8890/DAV/prot_domain>
from <http://localhost:8890/DAV/mutations>
from <http://localhost:8890/DAV/PMID_drug>
from <http://mor.nlm.nih.gov/uniprot>
from <http://localhost:8890/DAV/biopax>
from <http://mor.nlm.nih.gov/GO>
where{
  ?uniprot <http://www.w3.org/2000/01/rdf-schema#seeAlso> ?gene.
  FILTER (?y >= 1).
  ?uniprot <http://www.w3.org/2000/01/rdf-schema#seeAlso> ?react.
}
SPARQL Query

Find the NDF-RT drug “Warfarin” and get all of the pathways that the genes it affects are in

```
<table>
<thead>
<tr>
<th>pmid</th>
<th>mutation</th>
<th>gene</th>
<th>uniprot</th>
<th>name</th>
<th>pathway</th>
</tr>
</thead>
<tbody>
<tr>
<td>11588061</td>
<td>1559.ARG144CYS</td>
<td>1559</td>
<td>P11712</td>
<td>Cytochrome P450 2C9</td>
<td>Biological_oxidations</td>
</tr>
</tbody>
</table>
```
CHALLENGES
Challenges: Scalability

• Uniprot is a huge database
  – Has ~1.5 billion triples and exists as a file that is over 100 Gb
  – Loading it into Virtuoso, crashed our server, several times
  – Required upgrading to a more dedicated server with larger RAM
  – Optimization for speed is still required to accommodate large size
Challenges: Interoperability

• BioPAX’s ontology schema includes Reactome and BioCyc
  – Each DB interprets the common ontology differently
    • The same architecture is used to describe the same concept differently, which requires leaving the ontology to find a unifying descriptor and then coming back

• The solution to this is that both DB’s call all of their proteins in UniProt accessions
Challenges: Interoperability

• A protein can be identified in three ways
  – UniProt Accession
  – NCBI Protein GI
  – NCBI RefSeq (comes from sequence)

• All of the output from EMU is created into RefSeq accession format, while ~half of protein description data started as UniProt and half as RefSeq as a result of an attempt reaching completeness of genome
Solution

• All of the UniProt Accessions are converted into RefSeq NCBI Protein GI’s to facilitate bridging mutations at Protein level

• For general traversing purposes, specific isoform information is lost as Entrez Gene ID’s are converted into UniProt Accession
  – Isoforms can still be retrieved if purpose requires it

• RefSeq Accessions that have no UniProt equivalent are dead ends, but are retained in graph
Conclusions

• Our triple store can handle ~1.5 billion triples
• All nodes and edges link and traverse correctly
• Preliminary results
  – More results to be presented by Emily on Aug. 11
  – Results show that we can find the same class of drug interacting with the same types of domains, which is what you would expect
Future Directions

• To add additional functionality by including new resources, such as drug adverse events and a more general gene-to-disease knowledge base

• To submit our findings for the Pacific Symposium on Biocomputing workshop on Mining the Pharmacogenomics Literature
Acknowledgements

• I would like to thank the NLM its rich support while here
• Olivier Bodenreider, my mentor while here
• Emily Doughty and Jonathan Mortensen, who I have collaborated with
• Dr. Jianpeng Ma, my mentor at Rice
• May Cheh, for putting all of this together
• Dr. McDonald

Thank you
Things That I Have Learned

• When dealing with large quantities of data from disparate systems,
Project Rational

Existing web resources exist as Islands

While many resources are quite large, both in their scope and interlink ability with other databases, for example an Entrez Gene search result will let you see the presence of that gene within all of the other tools featured by NCBI in addition to multiple pathway and gene expression databases generated by others.

This allows the user the jump between to Islands and to search many Islands at once.

However, this process is not suited well for batch queries across multiple databases, or for taking the result from one database and seeing how relates to a number of different things within a second database.

Or for propagating a query across multiple DB’s where the results from one DB become input for the next
Drug Properties


Created by the Veterans Health Administration, it is:

- A concept-oriented terminology
- Organized into hierarchies of concepts based on generalization
- A listing of drugs by their ingredients, method of action, diseases that are treated, physiologic effect, drug interactions, and drug class